Literature DB >> 25893668

Expression of spermidine/spermine N(1) -acetyl transferase (SSAT) in human prostate tissues is related to prostate cancer progression and metastasis.

Wei Huang1, Jens C Eickhoff2, Farideh Mehraein-Ghomi3, Dawn R Church3, George Wilding3, Hirak S Basu3.   

Abstract

INTRODUCTION: Prostate cancer (PCa) in many patients remains indolent for the rest of their lives, but in some patients, it progresses to lethal metastatic disease. Gleason score is the current clinical method for PCa prognosis. It cannot reliably identify aggressive PCa, when GS is ≤ 7. It is shown that oxidative stress plays a key role in PCa progression. We have shown that in cultured human PCa cells, an activation of spermidine/spermine N(1) -acetyl transferase (SSAT; EC 2.3.1.57) enzyme initiates a polyamine oxidation pathway and generates copious amounts of reactive oxygen species in polyamine-rich PCa cells.
METHOD: We used RNA in situ hybridization and immunohistochemistry methods to detect SSAT mRNA and protein expression in two tissue microarrays (TMA) created from patient's prostate tissues. We analyzed 423 patient's prostate tissues in the two TMAs.
RESULTS: Our data show that there is a significant increase in both SSAT mRNA and the enzyme protein in the PCa cells as compared to their benign counterpart. This increase is even more pronounced in metastatic PCa tissues as compared to the PCa localized in the prostate. In the prostatectomy tissues from early-stage patients, the SSAT protein level is also high in the tissues obtained from the patients who ultimately progress to advanced metastatic disease. DISCUSSION: Based on these results combined with published data from our and other laboratories, we propose an activation of an autocrine feed-forward loop of PCa cell proliferation in the absence of androgen as a possible mechanism of castrate-resistant prostate cancer growth.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  SSAT; biomarker for progression; cancer prognosis; oxidative Stress

Mesh:

Substances:

Year:  2015        PMID: 25893668      PMCID: PMC4475436          DOI: 10.1002/pros.22996

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  36 in total

Review 1.  Triggers for genomic rearrangements: insights into genomic, cellular and environmental influences.

Authors:  Ram-Shankar Mani; Arul M Chinnaiyan
Journal:  Nat Rev Genet       Date:  2010-11-03       Impact factor: 53.242

2.  Heparin affin regulatory peptide/pleiotrophin mediates fibroblast growth factor 2 stimulatory effects on human prostate cancer cells.

Authors:  Maria Hatziapostolou; Christos Polytarchou; Panagiotis Katsoris; Jose Courty; Evangelia Papadimitriou
Journal:  J Biol Chem       Date:  2006-08-29       Impact factor: 5.157

3.  NF-κB is 25.

Authors:  David Baltimore
Journal:  Nat Immunol       Date:  2011-07-19       Impact factor: 25.606

4.  Properties of recombinant human N1-acetylpolyamine oxidase (hPAO): potential role in determining drug sensitivity.

Authors:  Yanlin Wang; Amy Hacker; Tracy Murray-Stewart; Benjamin Frydman; Aldonia Valasinas; Alison V Fraser; Patrick M Woster; Robert A Casero
Journal:  Cancer Chemother Pharmacol       Date:  2005-03-25       Impact factor: 3.333

Review 5.  The role of oxidative stress in prostate cancer.

Authors:  Gaytri Gupta-Elera; Andrew R Garrett; Richard A Robison; Kim L O'Neill
Journal:  Eur J Cancer Prev       Date:  2012-03       Impact factor: 2.497

6.  Regulation of activity and function of the p52 NF-κB subunit following DNA damage.

Authors:  Benjamin Barré; Olivier Coqueret; Neil D Perkins
Journal:  Cell Cycle       Date:  2010-12-15       Impact factor: 4.534

7.  B-cell-derived lymphotoxin promotes castration-resistant prostate cancer.

Authors:  Massimo Ammirante; Jun-Li Luo; Sergei Grivennikov; Sergei Nedospasov; Michael Karin
Journal:  Nature       Date:  2010-03-11       Impact factor: 49.962

8.  Implications of pleiotrophin in human PC3 prostate cancer cell growth in vivo.

Authors:  Sotiria Tsirmoula; Kostas Dimas; Maria Hatziapostolou; Margarita Lamprou; Panagiota Ravazoula; Evangelia Papadimitriou
Journal:  Cancer Sci       Date:  2012-08-14       Impact factor: 6.716

9.  A small molecule polyamine oxidase inhibitor blocks androgen-induced oxidative stress and delays prostate cancer progression in the transgenic adenocarcinoma of the mouse prostate model.

Authors:  Hirak S Basu; Todd A Thompson; Dawn R Church; Cynthia C Clower; Farideh Mehraein-Ghomi; Corey A Amlong; Christopher T Martin; Patrick M Woster; Mary J Lindstrom; George Wilding
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

10.  Nitric oxide stimulates migration of human endothelial and prostate cancer cells through up-regulation of pleiotrophin expression and its receptor protein tyrosine phosphatase beta/zeta.

Authors:  Christos Polytarchou; Maria Hatziapostolou; Evangelia Poimenidi; Constantinos Mikelis; Ariadni Papadopoulou; Anastasia Parthymou; Evangelia Papadimitriou
Journal:  Int J Cancer       Date:  2009-04-15       Impact factor: 7.396

View more
  17 in total

1.  A Novel Artificial Intelligence-Powered Method for Prediction of Early Recurrence of Prostate Cancer After Prostatectomy and Cancer Drivers.

Authors:  Wei Huang; Ramandeep Randhawa; Parag Jain; Samuel Hubbard; Jens Eickhoff; Shivaani Kummar; George Wilding; Hirak Basu; Rajat Roy
Journal:  JCO Clin Cancer Inform       Date:  2022-02

2.  MALAT1 Long Non-coding RNA Expression in Thyroid Tissues: Analysis by In Situ Hybridization and Real-Time PCR.

Authors:  Ranran Zhang; Heather Hardin; Wei Huang; Jidong Chen; Sofia Asioli; Alberto Righi; Francesca Maletta; Anna Sapino; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2017-03       Impact factor: 3.943

Review 3.  Non-Coding RNAs in Thyroid Cancer.

Authors:  Ranran Zhang; Heather Hardin; Jidong Chen; Zhenying Guo; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2016-03       Impact factor: 3.943

4.  Inhibitor of p52 NF-κB subunit and androgen receptor (AR) interaction reduces growth of human prostate cancer cells by abrogating nuclear translocation of p52 and phosphorylated AR(ser81).

Authors:  Farideh Mehraein-Ghomi; Dawn R Church; Cynthia L Schreiber; Ashley M Weichmann; Hirak S Basu; George Wilding
Journal:  Genes Cancer       Date:  2015-09

5.  Oxidative stress and prostatic diseases.

Authors:  Thierry Roumeguère; Joseph Sfeir; Elie El Rassy; Simone Albisinni; Pierre Van Antwerpen; Karim Zouaoui Boudjeltia; Nassim Farès; Joseph Kattan; Fouad Aoun
Journal:  Mol Clin Oncol       Date:  2017-09-19

Review 6.  Structure and Functional Diversity of GCN5-Related N-Acetyltransferases (GNAT).

Authors:  Abu Iftiaf Md Salah Ud-Din; Alexandra Tikhomirova; Anna Roujeinikova
Journal:  Int J Mol Sci       Date:  2016-06-28       Impact factor: 5.923

7.  Metabolite Analysis and Histology on the Exact Same Tissue: Comprehensive Metabolomic Profiling and Metabolic Classification of Prostate Cancer.

Authors:  Tao Huan; Dean A Troyer; Liang Li
Journal:  Sci Rep       Date:  2016-08-31       Impact factor: 4.379

8.  Expression of the SIBLINGs and their MMP partners in human benign and malignant prostate neoplasms.

Authors:  Charles C Anunobi; Komal Koli; Geetu Saxena; Adekunbiola A Banjo; Kalu U E Ogbureke
Journal:  Oncotarget       Date:  2016-07-26

9.  Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy.

Authors:  Peder R Braadland; Guro Giskeødegård; Elise Sandsmark; Helena Bertilsson; Leslie R Euceda; Ailin F Hansen; Ingrid J Guldvik; Kirsten M Selnæs; Helene H Grytli; Betina Katz; Aud Svindland; Tone F Bathen; Lars M Eri; Ståle Nygård; Viktor Berge; Kristin A Taskén; May-Britt Tessem
Journal:  Br J Cancer       Date:  2017-10-03       Impact factor: 7.640

10.  Spermidine/spermine N1-acetyltransferase-1 as a diagnostic biomarker in human cancer.

Authors:  Andrew W Maksymiuk; Daniel S Sitar; Rashid Ahmed; Brian Cheng; Horacio Bach; Rushita Adhikari Bagchi; Nina Aroutiounova; Paramjit S Tappia; Bram Ramjiawan
Journal:  Future Sci OA       Date:  2018-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.